Physician profile
Mohammed A Memon
NPI 1609826668
$6,238.40
in general payments reported to CMS, 2019-2025
28 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $1,229 · 2021: $1,356 · 2022: $895 · 2023: $735 · 2024: $727 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,673.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $787.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $562.04 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.70 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $495.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $347.25 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $329.63 | 2021-2023 | |
| Exact Sciences Corporation | $203.72 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $176.20 | 2019-2021 | |
| Allergan, INC. | $163.10 | 2020 | |
| Phathom Pharmaceuticals, INC. | $142.23 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $99.29 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $87.53 | 2022-2025 | Zoryve, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $82.97 | 2022-2023 | Eliquis |
| Horizon Therapeutics Plc | $74.45 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $70.66 | 2022-2023 | |
| Seqirus USA INC | $65.32 | 2023-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Genentech USA, INC. | $58.95 | 2020-2021 | |
| Abbott Laboratories | $53.59 | 2021-2022 | |
| Amgen INC. | $40.80 | 2023-2025 | Otezla, Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $40.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.00 | 2023 | Xifaxan |
| Gilead Sciences, INC. | $20.45 | 2019 | |
| Lifescan, INC. | $20.30 | 2022 | |
| Hologic Sales and Service, LLC | $16.52 | 2021 | |
| Merck Sharp & Dohme LLC | $16.12 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.87 | 2021 | |
| Insulet Corporation | $15.03 | 2024 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.